NeoGenomics Hurricane Ian Emergency Response
Important Announcement
Dear Valued Client,
Over the last week, we have closely monitored Hurricane Ian
as it enters the Gulf of Mexico and is making landfall on the southwest coast
of Florida as a Category 4 hurricane. We have established a Hurricane Ian Emergency
Response Team to focus all our efforts on business continuity for our Fort
Myers and Tampa, Florida facilities.
Our number one priority is patient care. We have been working
around the clock for several days and have focused our efforts to ensure
patient samples that would be performed in Florida are performed elsewhere
within our extensive network across the country and that turnaround time delays
are minimized.
Simultaneously, we have activated a plan to support the
safety and well-being of our NeoGenomics employees and their families.
Communication is a critical component of our emergency
response plan and over the next several days and weeks, you can expect regular updates.
As of today, here is what you should know:
·
Logistics: We have
taken steps to re-route inbound Florida samples.
·
Staffing: We have
re-directed all resources to our other clinical labs within our network to
prioritize in-bound clinical samples, including re-allocating technical staff
from our pharma services division.
·
Fort Myers,
FL Headquarters: Our Fort Myers HQ is designed to withstand a
Category 5 Hurricane and we are ready re-start operations once our FedEx and
courier teams can resume services and our employees can safely return to this
facility.
·
Resource
allocation: We have allocated all resources to the Hurricane Ian
Emergency Response Team and will spare no expense to ensure our patients and
employees come first as we navigate thru this storm.
On a personal note, I am humbled, inspired and so incredibly
proud of our Neo family, as they bring to life our Mission to “save lives by
improving patient care.” Our values of Teamwork, Quality and Accountability are
shining through during this difficult time.
If you have any questions, please
feel free to contact our Client Services team at (877) 776-5907.
Warmest regards,
Chris Smith,
Chief Executive Officer
NeoGenomics Laboratories
9/28/2022
IHC/ISH
CMV ISH - Effective Monday, October 10th, CMV ISH will return to
our testing menu and be available for ordering. CMV ISH is useful for detection
of primary, latent, and reactivated CMV infections in FFPE tissues. Please
Note: For clients ordering using paper requisitions, please write-in this test
order, as the requisitions will not yet reflect this offering.
- CPT: 88365 x 1
- Level of Service: Global
Level of Service
Displayed in Online Orders and Interfaced Orders - Effective Monday, October 10th, Online Orders 1.0, 2.0, and
Interfaced Orders will be updated to accurately reflect the Level of Service
offerings for our Technical IHC and ISH tests. For the most current listing of
our test offerings and service levels, please refer to our online
test menu.
The CPT codes provided with our
test descriptions are based on AMA guidelines and are for informational
purposes only. Correct CPT coding is the sole responsibility of the billing
party. Please direct any questions regarding coding to the payor being billed.
Special Announcements
RET fusions are
now approved targets in all solid tumor types
Last week the FDA issued the first approval of a RET-fusion targeted therapy
for use against all types of solid tumor. Details are available here.
NeoGenomics provides options for highly sensitive RNA-based NGS detection of
RET fusions. NTRK
& RET NGS Fusion Panel is a compact pan-tumor test, while the Targeted
Solid Tumor NGS Fusion Panel covers 19 genes most relevant to
fusion-targeted therapies and clinical trial options. Please contact your
NeoGenomics Sales Consultant for additional NGS and FISH test options.
For interface-related test
changes that are taking effect on Monday October 9th, click here
for a downloadable document to view the impacted interface test codes. Several
Histology test codes will be discontinued.
If you have interface
questions, please contact InterfaceTeam@Neogenomics.com